Immunome Announces Proposed Public Offering of Common Stock
14 2월 2024 - 6:05AM
Business Wire
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology
company dedicated to developing first-in-class and best-in-class
targeted cancer therapies, today announced its plans to commence an
underwritten public offering, subject to market and other
conditions, to issue and sell $200.0 million of shares of its
common stock. All of the shares are being offered by Immunome. In
connection with the proposed offering, Immunome expects to grant
the underwriters a 30-day option to purchase up to an additional
15% of the shares of its common stock sold in the public offering.
There can be no assurance as to whether or when the proposed
offering may be completed or as to the actual size or terms of the
proposed offering.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim
Securities are acting as joint book-running managers for the
proposed offering. Wedbush PacGrow is acting as lead manager for
the proposed offering.
The proposed offering is being made pursuant to a shelf
registration statement on Form S-3 that was filed with the U.S.
Securities and Exchange Commission (the "SEC") on February 13, 2024
and automatically became effective upon filing. A preliminary
prospectus supplement and accompanying prospectus relating to the
proposed offering will be filed with the SEC and will be available
for free on the SEC’s website located at http://www.sec.gov. Copies
of the preliminary prospectus supplement and the accompanying
prospectus relating to the proposed offering may be obtained, when
available from: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; Leerink
Partners LLC, Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or
by email at syndicate@leerink.com; or Guggenheim Securities, LLC
Attention: Equity Syndicate Department, 330 Madison Avenue, New
York, NY 10017 or by telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including ADCs, radioligand therapies, immunotherapies,
and small molecules. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
Forward-Looking Statements
Statements contained in this press release regarding Immunome’s
expectations regarding the offering are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include
statements regarding, among other things, Immunome’s expectations
regarding the completion, timing and size of the proposed offering
and with respect to granting the underwriters a 30-day option to
purchase additional shares. These forward-looking statements are
based upon Immunome’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, market
conditions, size and expected gross proceeds of the offering, the
satisfaction of customary closing conditions related to the
proposed offering, Immunome's ability to complete the proposed
offering, and the risks and uncertainties inherent in Immunome’s
business. These and other risks and uncertainties are described in
greater detail in the section entitled “Risk Factors” in Immunome's
most recent annual report on Form 10-K and quarterly report on Form
10-Q filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Immunome's other
filings with the SEC, including those contained or incorporated by
reference in the preliminary prospectus supplement and accompanying
prospectus related to the offering to be filed with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management’s assumptions and estimates as of such date. Immunome
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213516014/en/
Investor Contact: Max Rosett Interim Chief Financial
Officer and EVP, Operations mrosett@immunome.com
Immunome (NASDAQ:IMNM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Immunome (NASDAQ:IMNM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024